Previous Close | 1.9000 |
Open | 1.9000 |
Bid | 0.0000 |
Ask | 3.8000 |
Strike | 2.50 |
Expire Date | 2024-05-17 |
Day's Range | 1.9000 - 1.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 55 |
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
Strategic Advances Amidst Financial Prudence